Louisiana State Employees Retirement System maintained its stake in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) during the second quarter, according to its most recent filing with the SEC. The firm owned 30,000 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Louisiana State Employees Retirement System’s holdings in Impax Laboratories were worth $483,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Comerica Bank boosted its stake in shares of Impax Laboratories by 3.6% in the first quarter. Comerica Bank now owns 81,477 shares of the specialty pharmaceutical company’s stock valued at $1,124,000 after buying an additional 2,869 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Impax Laboratories by 11.8% in the first quarter. BNP Paribas Arbitrage SA now owns 15,029 shares of the specialty pharmaceutical company’s stock valued at $190,000 after buying an additional 1,588 shares during the period. American Century Companies Inc. acquired a new stake in shares of Impax Laboratories during the first quarter valued at approximately $1,195,000. Great West Life Assurance Co. Can boosted its stake in shares of Impax Laboratories by 7.6% in the first quarter. Great West Life Assurance Co. Can now owns 103,506 shares of the specialty pharmaceutical company’s stock valued at $1,304,000 after buying an additional 7,298 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Impax Laboratories by 7.8% in the first quarter. Canada Pension Plan Investment Board now owns 481,200 shares of the specialty pharmaceutical company’s stock valued at $6,087,000 after buying an additional 34,700 shares during the period. 83.48% of the stock is owned by institutional investors and hedge funds.

Impax Laboratories, Inc. (IPXL) traded up 0.55% during mid-day trading on Friday, reaching $18.30. The company had a trading volume of 1,600,694 shares. The firm’s 50-day moving average price is $17.34 and its 200-day moving average price is $14.34. The stock’s market cap is $1.31 billion. Impax Laboratories, Inc. has a 12 month low of $7.75 and a 12 month high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The company had revenue of $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. During the same period in the prior year, the business posted $0.21 EPS. The company’s quarterly revenue was up 17.1% on a year-over-year basis. Equities research analysts forecast that Impax Laboratories, Inc. will post $0.68 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/12/louisiana-state-employees-retirement-system-has-483000-position-in-impax-laboratories-inc-ipxl.html.

Several brokerages have recently commented on IPXL. Canaccord Genuity began coverage on Impax Laboratories in a research report on Monday, July 31st. They issued a “hold” rating and a $19.00 target price for the company. Zacks Investment Research cut Impax Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday, July 24th. Deutsche Bank AG set a $21.00 target price on Impax Laboratories and gave the stock a “buy” rating in a research report on Monday, July 17th. Piper Jaffray Companies raised Impax Laboratories from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $9.00 to $16.00 in a research report on Tuesday, July 18th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $62.00 target price (up previously from $10.00) on shares of Impax Laboratories in a research report on Thursday, May 11th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.56.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.